Strategic Biomarkers for Drug Development in Treating Rare Diseases and Diseases in Neonates and Infants
Journal Title: The AAPS Journal - Year 2013, Vol 15, Issue 2
Abstract
There are similar challenges in developing a product designed to treat patients with a rare disease and drugs to treat critically ill neonates and infants. Part of the challenge in developing such products as well as identifying the optimal dosing regimen for the treatment of young children arises from the complex interrelationship between developmental changes and changes in biomarkers responsive to drug therapy. These difficulties are further compounded by our lack of understanding of the key physiological factors that cause the differences in clinical responses between adults and neonates and infants. Regulatory efforts have succeeded in overcoming these challenges in many areas of pediatric and orphan drug development. Strategic applications of biomarkers and surrogate endpoints for the development and approval of a product used to treat an orphan disease will be highlighted with examples of approved products. Continued efforts are still needed to fill in our knowledge gap and to strategically link biomarkers and surrogate endpoints to clinical responses for rare diseases and diseases affecting neonates and infants.
Authors and Affiliations
Jane P. F. Bai, Jeffrey S. Barrett, Gibert J. Burckart, Bernd Meibohm, Hari Cheryl Sachs, Lynne Yao
Keywords
Related Articles
- EP ID EP681114
- DOI 10.1208/s12248-013-9452-z
- Views 79
- Downloads 0
Neuro-fuzzy Models as an IVIVR Tool and Their Applicability in Generic Drug Development
The online version of this article (doi:10.1208/s12248-014-9569-8) contains supplementary material, which is available to authorized users.
Pilot and Repeat Trials as Development Tools Associated with Demonstration of Bioequivalence
The online version of this article (doi:10.1208/s12248-015-9744-6) contains supplementary material, which is available to authorized users.
Non-Arrhenius Protein Aggregation
Protein aggregation presents one of the key challenges in the development of protein biotherapeutics. It affects not only product quality but also potentially impacts safety, as protein aggregates have been shown to be l...
Modeling and simulation of adherence: Approaches and applications in therapeutics
Partial adherence with a prescribed or randomly assigned dose gives rise to unintended variability in actual drug exposure in clinical practice and during clinical trials. There are tremendous costs associated with incom...
Biochemical Modulation of Aracytidine (Ara-C) Effects by GTI-2040, a Ribonucleotide Reductase Inhibitor, in K562 Human Leukemia Cells
GTI-2040 is a potent antisense to the M2 subunit of the ribonucleotide reductase (RNR), an enzyme involved in the de novo synthesis of nucleoside triphosphates. We hypothesized that combination of GTI-2040 with the cytar...